[Peptidoleukotriene receptor antagonists in asthma therapy].
Peptidoleukotrienes reproduce some of the functional and histological features of clinical asthma, such as potent bronchoconstriction, airway microvascular leakage, mucus hypersecretion, eosinophilic airway infiltration, in addition to inducing bronchial hypersensitivity. An important role for peptidoleukotrienes has been demonstrated in experimental challenge studies in asthmatic patients and in acute asthma attacks. Antagonists of peptidoleukotrienes can inhibit bronchoconstriction in response to inhaled allergen, exercise or inhaled cold air, and oral or inhaled aspirin. These compounds demonstrate beneficial effects in clinical studies with improvement in symptoms and lung function. Peptidoleukotriene antagonists may provide a new therapeutic approach for the treatment of asthma.
Sakakibara
H
H
Department of Internal Medicine, Fujita Health University School of Medicine.
Hirose
K
K
Okawara
S
S
D001249:Asthma / Q000188:drug therapy* / Q000209:etiology; D002867:Chromones / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D011422:Propionates / Q000494:pharmacology / Q000627:therapeutic use*; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D013189:SRS-A / Q000378:metabolism / Q000502:physiology; D013449:Sulfonamides; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D014105:Tosyl Compounds / Q000494:pharmacology / Q000627:therapeutic use*
D002867:Chromones; D007211:Indoles; D020024:Leukotriene Antagonists; D048448:Phenylcarbamates; D011422:Propionates; D011804:Quinolines; D013189:SRS-A; D013449:Sulfonamides; D013777:Tetrazoles; D014105:Tosyl Compounds; C059101:RG 12525; C059141:verlukast; C047681:pranlukast; C062735:zafirlukast